ReviewPharmaceutics2026
Advances in Living Cell-Mediated Nanodrug Delivery Systems: Construction Strategies, Applications and Challenges.
Review in Pharmaceutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Nanodrug delivery systems have shown great promise against tumors, inflammatory diseases and central nervous system disorders. However, several limitations still exist before further clinical application. The unsatisfactory circulation time in vivo, rapid clearance by the mononuclear phagocyte system, insufficient tissue penetration and low targeting efficiency all hinder the clinical translation of nanomedicines. Cells are the fundamental functional units of the body and their intrinsic biological properties make them promising drug delivery vehicles for targeted therapy. Conjugating cells with nanomedicines combines the carrier functions of living cells with the therapeutic effects of nanodrugs, offering an effective strategy to improve targeted drug delivery. Compared with the existing literature, this review specifically summarizes the biological properties and major applications of six types of living cell carriers. The recent strategies for constructing cell-nanomedicine conjugates are also discussed. Finally, we highlight the current challenges for clinical translation and discuss future directions for the development of cell-nanomedicine delivery systems.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.